Page 2 - Astrazeneca Medimmune News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Astrazeneca medimmune. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Astrazeneca Medimmune Today - Breaking & Trending Today

First-Line NALIRIFOX Demonstrates Survival Advantage Over Standard Gemcitabine/Paclitaxel in Metastatic PDAC

Eileen M. O’Reilly, MD, expands on the updated survival data from NAPOLI-3, explains how NALIRIFOX could fit into the current pancreatic ductal adenocarcinoma treatment paradigm, and shares potential opportunities to build upon this research moving forward. ....

United States , Los Angeles , New York , Astrazeneca Medimmune , Genentech Roche , Eileenm Oreilly , Zev Wainberg , Bristol Myers Squibb , University Of California , Los Angeles Health , Pancreatic Cancer Research , Davidm Rubenstein Center , Boehringer Ingelheim , Helio Health Incyte , Winthrop Rockefeller Endowed Chair , Medical Oncology , Medical Initiatives , Pancreatic Cancer , Neuroendocrine Cancers , Memorial Sloan Kettering Cancer Center , Cancers Symposium , North America , North American , Autem Medical , Helio Health , Marcus Ventures ,

ctDNA negative status contributes to positive outcomes for DLBCL

ctDNA negative status contributes to positive outcomes for DLBCL
healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.

United States , Bristol Myers Squibb , Genentech Roche , Katrina Altersitz , Adicet Bio , Bycory Perla , Astrazeneca Medimmune , Alex Herrera , Tubulis Gmb , American Society Of Clinical Oncology Meeting , Gilead Sciences , American Society , Clinical Oncology Meeting , Caribou Biosciences , Karyopharm Therapeutics ,

First-line Enfortumab Vedotin Plus Pembrolizumab Has Durable Activity in Urothelial Carcinoma

Responses achieved with enfortumab vedotin plus pembrolizumab were found to be rapid and durable in patients with previously untreated locally advanced or metastatic urothelial carcinoma who were cisplatin ineligible. ....

San Francisco , United States , Astellas Pharma , Genentech Roche , Roche Genentech , Astrazeneca Medimmune , Bristol Myers Squibb , Terence Friedlander , University Of California , Cancer Research , Helen Diller Family Comprehensive Cancer Center , Division Of Hematology Oncology , Foundation Medicine , Affairs Inc , Zuckerberg San Francisco General , Dava Oncology , Taiho Oncology , Neon Therapeutics , Astellas Scientific , Medical Affairs Inc , Med Biogene , Immuno Oncology , Urothelial Cancer , Ucsf Helen Diller Family Comprehensive Cancer Center ,

Post-Hoc Analysis Confirms Safety of Maintenance Avelumab in Urothelial Carcinoma

The addition of first-line maintenance avelumab to best supportive care has sustained tolerability in patients with advanced urothelial carcinoma. ....

United States , Dana Farber Cancer Institute , Astellas Pharma , Joaquim Bellmunt , Astrazeneca Medimmune , Pierre Fabre , Bristol Myers Squibb , Rainier Therapeutics , Uptodate Bladder Cancer ,

Pembrolizumab plus axitinib shows durable benefit in clear cell renal cell carcinoma

CHICAGO — Pembrolizumab plus axitinib continued to confer a survival benefit vs. sunitinib at 5-year follow-up as first-line therapy for patients with advanced clear cell renal cell carcinoma, according to study results. The long-term data, presented at ASCO Annual Meeting, showed improved outcomes with the combination even though more patients in the sunitinib group had subsequent ....

United States , Bymatthew Shinkle , Brian Rini , Mindy Valcarcel , Genentech Incyte , Briani Rini , Astrazeneca Medimmune , Life Sciences , Vanderbilt University Medical Center , Bristol Myers Squibb ,